A study of the detection of potential adverse drug events or interactions found that using PGx information led to better prediction of serious issues, despite no significant change overall.
A new poll finds most US adults are not familiar with personalized medicine, according to HealthDay.
After raising $320M in venture capital, Tempus hopes to sequence 100,000 samples in 2019 as it expands its precision medicine program into depression and diabetes.
In order to be eligible for the drug, patients must have NTRK fusions, which may be determined via various tests including NGS and FISH.
In the I-SPY 2 trial, investigators analyzed whether MammaPrint scores and BluePrint subtypes could help identify patients who would respond better to treatments.
A start-up company aiming to match cancer patients to treatments closes after about six weeks, Stat News reports.
Scripps Research Translational Institute has teamed with Nvidia to create a center of excellence for AI in genomics and wearable sensors.
HudsonAlpha's Genome Gateway collects family histories and facilitates secure communication between patients, clinicians, and researchers.
Stanford University's Michael Snyder found that methylome shifts preceded spikes in his blood glucose levels, suggesting profiling could detect disease.
Kaiser Health News reports on the high cost of targeted cancer therapies.
The data generated by 100,000 Genomes Project is being housed on military servers due to attacks by hackers, Naked Security reports.
Vox reports that the United Nations' Convention on Biological Diversity decided against a gene drive moratorium.
In Science this week: sequencing of neuroblastomas uncovers alterations linked to prognosis, and more.